From the FDA Drug Label
Renal function should be evaluated prior to initiation of JARDIANCE and monitored periodically thereafter. More frequent renal function monitoring is recommended in patients with an eGFR below 60 mL/min/1.73 m2.
Renal Function Monitoring Schedule:
- Evaluate renal function prior to initiating JARDIANCE.
- Monitor renal function periodically thereafter.
- More frequent monitoring is recommended for patients with an eGFR below 60 mL/min/1.73 m2. 1
From the Research
Renal function should be assessed before starting Jardiance (empagliflozin) and then periodically during treatment, with eGFR measured at baseline, then at least annually, and more frequently in patients at higher risk for renal impairment, as supported by the most recent study 2.
Monitoring Schedule
The monitoring schedule for renal function when initiating Jardiance (Empagliflozin) therapy is crucial due to its mechanism of action and potential effects on renal hemodynamics.
- eGFR should be measured at baseline
- Then at least annually
- More frequently in patients at higher risk for renal impairment, such as those with an eGFR below 45 mL/min/1.73 m², who may require monitoring every 3-6 months 3.
Dose Adjustment and Discontinuation
- If eGFR falls persistently below 45 mL/min/1.73 m², consider dose reduction to 10 mg daily.
- Jardiance should be discontinued if eGFR falls persistently below 30 mL/min/1.73 m², as indicated by the latest research findings 2.
Patient Risk Factors
Patients with risk factors such as older age, concomitant diuretic use, or history of kidney disease may need more frequent monitoring than the standard recommendation, highlighting the importance of individualized care 4.
Empagliflozin's Renoprotective Effects
Empagliflozin has been shown to have renoprotective effects, slowing the progression of chronic kidney disease in patients with type 2 diabetes and cardiovascular disease, which supports its use in patients with renal impairment 5.